Remote Monitoring and Optimization of Heart Failure Therapy

NCT07622472 · tracked via the Priya Life Science France tracker

Sponsor

Zoll Medical Corporation

Phase

Not applicable

Started

2026-10-01

Last updated

2026-06-26

Condition(s) studied

Heart Failure

Investigational drug(s) / intervention(s)

Wearable Monitoring Device for Heart Failure

Wearable Monitoring Device for Heart Failure: Participants assigned to the intervention group will use a noninvasive wearable physiological monitoring device (Heart Failure Management System, HFMS) designed to continuously collect data related to cardiopulmonary status, including heart rate, respiratory parameters, activity levels, and indicators of fluid status (Thoraic Fluid Index = TFI). Clinical care teams perform regular reviews of device-derived data and may respond to alerts or trends suggestive of worsening heart failure. Based on these data, the care team may adjust patient management, including modification of guideline-directed medical therapy or scheduling of follow-up assessments. The device does not deliver therapy and is used to support clinical decision-making in the outpatient management of heart failure.

Study summary

Heart failure is a condition in which the heart cannot pump blood effectively, often leading to symptoms such as shortness of breath and fluid retention. After hospitalization for heart failure, patients remain at high risk of worsening symptoms, emergency visits, and hospital readmission.

This study is designed to evaluate whether using a wearable monitoring device, called the Heart Failure Management System (HFMS), can help improve the management of patients after a recent hospitalization for heart failure.

Participants in this study will be randomly assigned to one of two groups. One group will receive standard medical care alone. The other group will receive standard medical care in combination with the HFMS device. The HFMS device is worn on the body and continuously collects information such as heart rate, breathing, activity level, and signs of fluid accumulation. These data are reviewed by the clinical care team and may help detect early worsening of heart failure.

Participants will wear the device for 90 days (if assigned to the device group) and will be followed for up to one year. During the study, information will be collected on serious health events such as death, hospitalizations, emergency visits, and changes in heart failure status, as well as quality of life.

The goal of this study is to determine whether this monitoring approach can improve outcomes for patients with heart failure by enabling earlier and more effective clinical management.

Eligibility

Sex

ALL

Min age

18 Years

Max age

85 Years

Healthy volunteers

Inclusion Criteria: * Age ≥18 years * Ability and willingness to provide written informed consent and comply with study procedures * Hospital admission for acute heart failure with dyspnea at rest and pulmonary congestion on chest X-ray, and other signs and/or symptoms of heart failure such as edema and/or positive rales on auscultation. * All measures within 24 hours prior to randomization of systolic blood pressure ≥ 100 mmHg, and of heart rate ≥ 60 bpm. * All measures within 24 hours prior to randomization of serum potassium ≤ 5.5 mEq/L (mmol/L). * Biomarker criteria for persistent congestion: * NT-proBNP \>1500 pg/mL at the time of admission, and; * NT-proBNP \>1000 pg/mL \>=3 days after initial admission measure * At 1 week prior to admission, either (a) ≤ ½ the optimal dose of ACEi/ARB/ARNi (see Table) prescribed, no beta-blocker prescribed, and ≤ ½ the optimal dose of MRA prescribed or (b) no ACEi/ARB/ARNi prescribed, ≤ ½ the optimal dose of beta-blocker prescribed, and ≤ ½ the optimal dose of MRA prescribed. All study participants prescribed per label and commercially fit with the HFMS device will be eligible for enrollment. Exclusion Criteria: * Age \< 18 years * Clearly documented intolerance to high doses (≥50% of target dose) of beta-blockers. * Clearly documented intolerance to high doses (≥50% of target dose) of RAS blockers (both ACEi and ARB). * Mechanical ventilation (not including CPAP/BIPAP) in the 24 hours prior to Screening. * Significant pulmonary disease contributing substantially to the patients' dyspnea such as FEV1\< 1 liter or need for chronic systemic or nonsystemic steroid therapy, or any kind of primary right heart failure such as precapillary pulmonary hypertension or chronic thromboembolic pulmonary hypertension. * Cardiac surgery within 3 months prior to Screening * Index Event (admission for AHF) triggered primarily by a correctable etiology such as significant arrhythmia (e.g., sustained ventricular tachycardia, or atrial fibrillation/flutter with sustained ventricular response \>130 beats per minute, or bradycardia with sustained ventricular arrhythmia \<45 beats per minute), severe anemia, acute coronary syndrome, pulmonary embolism, planned admission for device implantation or severe nonadherence leading to very significant fluid accumulation prior to admission and brisk diuresis after admission. Troponin elevations without other evidence of an acute coronary syndrome are not excluded. * Uncorrected thyroid disease, active myocarditis, or known amyloid, sarcoidosis, or hypertrophic obstructive cardiomyopathy. * History of heart transplant or on a transplant list, or using or planned to be implanted with a ventricular assist device. * Adhesive allergy/sensitivity (e.g., acrylic adhesives). * Compromised skin at the device application site (wound, severe dermatitis, etc.) . * Having a prescribed wearable cardioverter defibrillator * Pulmonary artery pressure implant (e.g. CardioMems) * Expected survival \<1 year

Primary outcome measure(s)

Hierarchical Composite Outcome (Win Ratio) — 90 days
A hierarchical composite outcome comparing the intervention and control groups using a win ratio approach. The components are prioritized as follows: (1) cardiovascular death, (2) heart failure hospitalization, (3) Unplanned visit (emergency room or other emergency facilities) requiring intravenous diuretic treatment, and (4) change in NT-proBNP concentration. Participants are compared pairwise, with outcomes evaluated sequentially according to this hierarchy.

Trial sites (9)

Facility	City	Region
CHU Nancy	Nancy	Grand Est
Justus-Liebig University Giessen	Giessen	Germany
Policlinico Casilino	Roma	Italy
UMC Utrecht	Utrecht	Netherlands
PIM MSWiA Hospital	Warsaw	Poland
Hospital Universitario 12 de Octubre	Madrid	Spain
Uppsala University Hospital	Uppsala	Sweden
University Zurich	Zurich	Switzerland
Southampton University Hospital NHS Foundation Trust	Southampton	United Kingdom

Other trials for the same condition

Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor) Starting soon

Tolerability and Safety of CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients with Cardio Renal Syndrome with Severe Renal Impairment Recruiting

Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List Recruiting

AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation Starting soon

AMEND-CRT: Mechanical Dyssynchrony as Selection Criterion for CRT Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07622472 on ClinicalTrials.gov ↗ ← All trials in France